Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tepoxalin is a nonsteroidal anti-inflammatory drug (NSAID) approved for veterinary use, primarily in dogs and occasionally in cats. It is used to reduce inflammation and relieve pain associated with musculoskeletal disorders such as osteoarthritis and hip dysplasia. Tepoxalin acts as a dual inhibitor of cyclooxygenase (COX, especially COX‑2) and lipoxygenase (5‑LOX), thereby suppressing the biosynthesis of both prostaglandins and leukotrienes, which are key mediators of inflammation. The drug is administered orally, typically once daily due to its pharmacokinetics—rapid absorption with a short plasma half-life but prolonged activity from its active metabolite[1][2][4][7]. Zubrin tablets rapidly disintegrate in the mouth for ease of administration to animals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tepoxalin.